Archive for the 'Pemetrexed (Alimta)' Category
July 11th, 2006. Physical Instability of Frozen Pemetrexed Solutions in PVC Bags
Conclusions: Although pemetrexed is chemically stable for 90 days frozen at -20 degrees C, substantial numbers of microparticulates formed in pemetrexed diluted in the infusion solutions in PVC bags upon long-term frozen storage. The avoidance of freezing pemetrexed solutions in PVC bags is therefore warranted.
July 3rd, 2006. Alteration of pemetrexed excretion in the presence of acute renal failure and effusions: presentation of a case and review of the literature
Dialysis was unsuccessful in removing pemetrexed. Theoretical and practical approaches to management of similar cases are presented.
June 30th, 2006. Pemetrexed and malignant pleural mesothelioma
The principal clinical experiences of pemetrexed alone or in combination with other compounds, chiefly platinum and its derivative, are reported. The Italian study on 1114 cases of MPM treated over 30 months is discussed and the definitive results will be available after a complete external review of all responsive patients.
June 30th, 2006. Clinical studies of pemetrexed and gemcitabine combinations
This combination has been, and continues to be evaluated for the treatment of a number of malignancies, including non-small cell lung and ovarian cancer. A recently published randomized trial of different sequences has identified the sequence of pemetrexed on day 1 followed by gemcitabine on day 1 and gemcitabine on day 8, every 21 days as the most efficacious and least toxic sequence.
June 6th, 2006. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma
Conclusions: Intensity-modulated RT treatment for mesothelioma after EPP and adjuvant chemotherapy resulted in a high rate of fatal pneumonitis when standard dose parameters were used. We therefore recommend caution in the utilization of this technique. Our data suggest that with IMRT, metrics such as V5 and MLD should be considered in addition to V20 to determine tolerance levels in future patients.
Posted in Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Extrapleural Pneumonectomy (EPP), Full Archive, IMRT, Intrapleural Chemotherapy, Pemetrexed (Alimta), Pleural, Radiation, Surgery, Treatment, Trimodality Therapy, Type of Assessment:, Type of Mesothelioma: | No Comments »
April 28th, 2006. Pemetrexed, a Novel Antifolate Therapeutic Alternative for Cancer Chemotherapy
Premedication, including administration of steroids and vitamin supplements, has been shown to decrease the frequency and severity of pemetrexed toxicities. Pemetrexed should be used as a standard of care for unresectable MPM and recurrent metastatic NSCLC.
April 26th, 2006. Pemetrexed in thoracic cancer
This review focuses on the available evidence of a novel antifolate agent, pemetrexed, in the treatment of both of these thoracic malignancies. Current status, persisting controversies and future developments are discussed.
April 6th, 2006. Systemic chemotherapy in the management of malignant peritoneal mesothelioma
Conclusion: The pemetrexed–cisplatin combination has become the new standard of care for patients with unresectable malignant mesothelioma. Future strategies shall incorporate these novel agents into multimodality approaches at earlier stages of the disease. Given the low incidence of this disease, encouraging physicians to refer these patients to specialized centers and patients to participate in clinical trials is of utmost importance.
March 30th, 2006. Clinical activity of pemetrexed: a multitargeted antifolate anticancer agent
Phase III studies with pemetrexed have established a clinical role for this drug as a single agent in the second-line treatment of non-small cell lung cancer and in combination with cisplatin for the frontline treatment of unresectable malignant pleural mesothelioma. Clinical trials of pemetrexed alone or in combination with other chemotherapeutic agents have shown considerable activity in many tumor types including colorectal, pancreatic and breast cancer, and urothelial tumors.
March 20th, 2006. Phase II Study of Pemetrexed Plus Carboplatin in Malignant Pleural Mesothelioma
Conclusion: Treatment with pemetrexed and carboplatin was active and well tolerated in patients with MPM. Disease control rate, time to disease progression, and overall survival were similar to the results achieved with the standard regimen of pemetrexed and cisplatin, suggesting that the carboplatin combination could be an alternative option for these patients.
February 8th, 2006. Epidemiologic surveillance for primary prevention of malignant mesothelioma: the Italian experience
Conclusions: Despite some ReNam's limitations, identification of MM cases and analysis of modality of exposure, with standardized criteria, are a fundamental tool for primary prevention of asbestos related diseases.
January 16th, 2006. Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial
(11) In practice, given the absence of a better alternative, and pending the results of a second trial, the cisplatin + pemetrexed combination can be used as a first-line regimen for patients with pleural mesothelioma. However, pemetrexed cannot replace docetaxel in second-line treatment of non small cell lung cancer.
December 21st, 2005. Pemetrexed-associated urticarial vasculitis
However, little has been published about the characteristics of this rash or about its mechanism. In an attempt to contribute to the growing body of knowledge about this new agent, we describe a case in which a patient developed a rash secondary to urticarial vasculitis associated with pemetrexed.
December 21st, 2005. Malignant pleural mesothelioma (MPM) – 5 years of experience
Discussion: S rarely is the treatment of choice, once most of the patients have local advanced disease, old age and comorbilities The epithelium mesothelioma was the prevalent histological type and because of the few number of patients with other types, it was not possible to establish significant relationships between the histological type and the overall survival. The survival tends to increase, 3 patients were treated with second line Ct and 1 with third line Ct.
December 21st, 2005. Malignant mesothelioma: A ten years experience
Discussion: As demonstrated by the small series in ten years, malignant mesothelioma is a rare tumour. Relationship with asbestos exposure was proven in 67% of cases. Chemotherapy associated with talc pleurodesis increased survival and palliated symptoms.
Posted in Carboplatin, Causation, Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Full Archive, Gemcitabine (Gemzar), Occupational Asbestos Exposure, Pemetrexed (Alimta), Surgery, Treatment, Type of Assessment: | No Comments »
December 14th, 2005. Multimodality approach in management of malignant pleural mesothelioma
Cisplatin and mitomycin have demonstrated modest efficacy in management of distant tumor recurrence. Cisplatin and gemcitabine regimen as well as cisplatin/pemetrexed followed by 54Gy of adjuvant hemithorax radiation have been reported to improve the outcome.
December 14th, 2005. Mesothelioma: advances in chemotherapy
Some preliminary data from studies of second line chemotherapy is also available. Finally studies of targeted therapies such as anti-EGFR, anti VEGF and anti PDGF are underway but have not as yet demonstrated major therapeutic benefit.
Posted in Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, EGFR, Full Archive, Gemcitabine (Gemzar), Pemetrexed (Alimta), Raltitrexed (Tomudex), Treatment, Type of Assessment:, Vinorelbine | No Comments »
November 21st, 2005. Pemetrexed: A multitargeted antifolate
Conclusions: Pemetrexed is a multitargeted antifolate that has demonstrated antitumor activity in various tumor types as a single agent and
November 21st, 2005. Pemetrexed: a new cytotoxic agent in the development for first-line non-small-cell lung cancer
Dietary supplementation with low-dose folic acid and vitamin B12 significantly reduces the incidence and severity of toxicities without compromising the antitumor activity of pemetrexed. With its innovative mode of action, proven efficacy, favorable toxicity profile and convenient administration, pemetrexed represents a new therapeutic option for the treatment of advanced NSCLC.
November 21st, 2005. Standard therapy for the treatment of malignant pleural mesothelioma
In particular, pemetrexed produces response rates of up to 45%, and increases median survival to over 12 months when used in combination with cisplatin. This doublet-based chemotherapy regimen is now the standard therapy for the first-line treatment of MPM.
|
|  |
